key: cord-0778879-n9al2de3
authors: Moll, Matthew; Connors, Jean M.
title: When to use anticoagulation in COVID-19()
date: 2021-06-16
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.06.005
sha: 4253de7c0f440d681a790ade91ae634134345e86
doc_id: 778879
cord_uid: n9al2de3

nan

Early in the COVID-19 pandemic, infection with SARS-CoV-2 was noted to be associated with a coagulopathy (1) and high rates of VTE observed in ICU patients, leading many to escalate doses of anticoagulants in infected ICU patients, as described by Kollias and colleagues. Many single and multi-institution analyses found increased VTE rates in ICU patients, based in part on how aggressively patients were assessed for VTE. (2) In the first 210 patients with COVID-19 admitted to our institution, we found a 3-4 fold increase in cumulative incidence of VTE in the ICU patients compared to those on the ward, (3) resulting in a change in institutional practice to increased "intermediate" dose LMWH for thromboprophylaxis. Using propensity score matching, we found no difference in VTE or mortality with "intermediate dose" heparin anticoagulants, although with no concerning increase in major bleeding. (4) Review of past data on the effectiveness of standard dose VTE practice in ICU patients also factored into our decision making, as VTE rates where higher in this population than those on the wards. (5) Randomized controlled trials were launched to address appropriate dose of anticoagulants in hospitalized patients, both on the ward and in the ICU. Endpoints however were not just venous or arterial thrombosis but included organ failure and death, as data showing pulmonary microvascular thrombosis (6) suggested that death from hypoxemic respiratory failure was a result of COVID-19 associated coagulopathy. As Kollias and colleagues note and describe, we now have data from the published INSPIRATION trial comparing intermediate dose to standard dose heparin in ICU patients (7) , and the multiplatform merged ATTACC/REMAP-CAP/ACTIV-4A (mpRCT) comparing therapeutic dose heparin to standard dose in both moderately-and severelyill patients, although these data are not yet published in a peer reviewed journal. In both INSPIRATION and the multiplatform analysis in ICU patients, escalated dose of heparin did not result in a decrease in the outcome compared to standard dose. While Kollias suggests that "VTE represents the most relevant endpoint regarding anticoagulation" in the moderately ill patients in the ATTACC/REMPA-CAP/ACTIV-4A trial, use of therapeutic dose heparin conferred a survival benefit, with decrease in the composite outcome of organ support free days and death. With the staggering numbers of deaths across the globe from COVID-19, improved survival with anticoagulation is relevant.

Our findings that an increased dose of heparin did not affect rates of thrombosis or mortality in ICU patients are similar to the results of both INSPIRATION and the severely ill cohort of the mpRCT. Kollias, we, and others have suggested that the aggregate of these data indicate that the use of increased doses of heparins in severely ill patients may be too late to mitigate the thrombotic effects of COVID-19; starting earlier with higher doses of anticoagulants, as in the moderately-ill cohort of the mpRCT appears to be better. As pointed out by Kollias and colleagues, use of intermediate dose heparin in 95 patients admitted to the ward at their institution suggested improved outcomes (8) , supporting the findings in the moderately-ill arm of the multiplatform trial.

NCT04400799) are enrolling acutely infected symptomatic patients that do not require hospital admission, including ACTIV-4b which randomizes to placebo, aspirin 81 mg a day

Channing Division of Network Medicine, Brigham and Women's Hospital

Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital

Division of Hematology, Brigham and Women's Hospital

Connors contributed equally to writing this manuscript

COVID-19 and its implications for thrombosis and anticoagulation

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost

VTE in ICU Patients With COVID-19

Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU J o u r n a l P r e -p r o o f Journal Pre-proof patients: A propensity score-matched analysis

PROphylaxis for ThromboEmbolism in Critical Care Trial Investigators. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study